MicroRNAs, a subpopulation of regulators, are involved in breast cancer progression through regulating breast cancer stem cells (Review)

Fan, Xuemei; Chen, Wei; Fu, Ziyi; Zeng, Lihua; Yin, Yuan; Yuan, Hongyan

doi:10.3892/ol.2017.6867

Cited by 14 publications

(21 citation statements)

References 56 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21,22 Hence, several studies are assessing the clinical usefulness of these miRNAs as antimetastatic agents and/or as predictors of metastatic bone disease. 22,23 In particular, recent studies provided evidence that miR-200 family, miR-128, miR-99a, miR-29b, let-7 miRNA, miR-600, miR-34, and miR-30 act as tumour suppressor and inhibit BCa bone metastasis via multiple mechanisms. [21][22][23] Furthermore, recent observations highlighted that some miR-NAs regulate the expression of target genes and signal pathways of breast cancer stem cells (BCSC) and, in particular those involved in the regulation of BCSC stemness and/or malignant progression and drug resistance.…”

Section: Osteoclast and Osteoblast As Therapeutic Targetmentioning

confidence: 99%

“…22,23 In particular, recent studies provided evidence that miR-200 family, miR-128, miR-99a, miR-29b, let-7 miRNA, miR-600, miR-34, and miR-30 act as tumour suppressor and inhibit BCa bone metastasis via multiple mechanisms. [21][22][23] Furthermore, recent observations highlighted that some miR-NAs regulate the expression of target genes and signal pathways of breast cancer stem cells (BCSC) and, in particular those involved in the regulation of BCSC stemness and/or malignant progression and drug resistance. [22][23][24] Therefore, these miRNA are of clinical interest in the CSC-targeting therapies aimed at hindering tumour progression.…”

Section: Osteoclast and Osteoblast As Therapeutic Targetmentioning

confidence: 99%

“…[21][22][23] Furthermore, recent observations highlighted that some miR-NAs regulate the expression of target genes and signal pathways of breast cancer stem cells (BCSC) and, in particular those involved in the regulation of BCSC stemness and/or malignant progression and drug resistance. [22][23][24] Therefore, these miRNA are of clinical interest in the CSC-targeting therapies aimed at hindering tumour progression. On the other hand, cancer stemlike cells (CSCs),whose survival and maintenance is strongly guaranteed by the bone microenvironment, have recently been considered potential therapeutic targets for combined treatments directed to impair specific interactions between CSCs and bone microenvironment, which foster the homing and growth of malignant cells (Figure 1).…”

Section: Osteoclast and Osteoblast As Therapeutic Targetmentioning

confidence: 99%

“…25 In this regard, numerous investigations are evaluating the therapeutic potential of molecules which interfere with CSC-specific signalling pathways, or which target alterations in CSC metabolism, or which modify the adjuvant setting defined by dormancy. 13,[23][24][25] Alternatively, other studies are aimed at developing molecules that may reprogram CSC for differentiation or immunotherapy-based CSC-targeting agents. 13,16,24 However, as these drugs might, in turn, affect normal tissue stem cells, their pharmacological and toxicological profile should be carefully assessed in the clinical setting.…”

Section: Osteoclast and Osteoblast As Therapeutic Targetmentioning

confidence: 99%

“…1,2,11,13,20,25 This approach might also target occult micro-metastases before their development into clinically evident bone lesions, ultimately hindering bone relapse and disease progression. 2,11,13,16,20,22,23 However, this therapeutic option implies the identification of early stage breast cancer patients who are at high risk of developing bone metastases. For this purpose, emerging studies have highlighted a significant association between molecular subtype of BCawhich reflect phenotypic and genotypic variations of the biology of this tumour, and risk of bone metastasis.…”

Section: Osteoclast and Osteoblast As Therapeutic Targetmentioning

confidence: 99%

See 4 more Smart Citations

Current status and future directions in the treatment of bone metastases from breast cancer

Leto

2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Breast cancer (BCa) is a malignant disease which preferentially metastasizes to the bone. 1,2 The consequences of this complication, which occurs in ~70% of metastatic BCa patients, may result in skeletal-related events (SREs) which encompass debilitating pain, impaired mobility, hypercalcaemia, pathologic fractures, spinal cord or nerve root compression, and bone marrow infiltration. 2,3 These pathological conditions negatively affect the performance status, quality of life (QoL) and survival of these patients. 3,4 The clinical treatment of bone metastasis from breast cancer is essentially aimed at palliating pain, maintaining function and preventing SREs. 3,4 This treatment requires a multidisciplinary approach, which is costly to the health care system. 4,5 On the other hand, although the current therapeutic options, based on the systemic administration of antiresorptive agents, 6 radiopharmaceuticals 7 or local treatment such as radiation therapy, 8 radiofrequency ablation 9 or surgery, 10 are effective in decreasing the tumour burden and slowing bone metastasis by reducing the extent of bone destruction, they are

show abstract

Section: Osteoclast and Osteoblast As Therapeutic Targetmentioning

confidence: 99%

Section: Osteoclast and Osteoblast As Therapeutic Targetmentioning

confidence: 99%

Section: Osteoclast and Osteoblast As Therapeutic Targetmentioning

confidence: 99%

Section: Osteoclast and Osteoblast As Therapeutic Targetmentioning

confidence: 99%

Section: Osteoclast and Osteoblast As Therapeutic Targetmentioning

confidence: 99%

See 3 more Smart Citations

Current status and future directions in the treatment of bone metastases from breast cancer

Leto

2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

A modern look at the molecular-biological mechanisms of breast tumours in dogs

Bilyi

Gerdeva

Samoilіuk

et al. 2020

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

High morbidity and increase in the number of registrations of breast tumours in dogs, their wide application as biological models, discussion of numerous questions of oncogenesis, and the lack of a uniform/unified methodological approach to the study of molecular and biological mechanisms of treatment of cancer determine the relevance of the problem of cancer both in humans and in our domestic companions. The analysis of publications allowed us to establish the following patterns of carcinogenesis. The peculiarities of the biological behaviour of breast tumours depend on their pathomorphological structure. Genetic predisposition to breast cancer is characteristic only in the single breed aspect. Environmental factors are of critical relevance to carcinogenesis : chemical pollutants initiate oncogenesis indirectly – by altering the expression of several receptors, impaired endocrine balance and direct mutagenic effects. Reproductive status plays a key role in the initiation and progression of breast tumours by reducing the expression of estrogen, progesterone and prolactin receptor genes. The inflammatory response that accompanies the neoplasia process is characterized by increased production of cytokines, cyclooxygenase-2, interleukins (IL-1, IL-6, IL-8), vascular endothelial growth receptors, and impaired hemostatic status (oxidative stress), which promotes progression of disease. In breast cancer in dogs, genomic instability leads to genomic aberrations, and subsequently, mutations that support the proliferation, survival and dissemination of neoplastic cells. The initiation and progression of mammary gland tumours is provided by cancer stem cells by disrupting the regulation of precursor cell self-renewal, which also predispose to resistance to chemotherapeutic agents, radiation, and hormonal cancer therapy. The analysis of the publications revealed the major markers of carcinogenesis that could potentially be used as biological targets for the design of modern diagnostic strategies and high-performance therapeutic protocols.

show abstract

The protective effects of miR-128-3p on sevoflurane-induced progressive neurotoxicity in rats by targeting NOVA1

Sun

et al. 2022

J. Toxicol. Sci.

View full text Add to dashboard Cite

MiR-128 is highly expressed in the central nervous system and may regulate the directional differentiation of bone marrow stromal stem cells into nerve cells. However, its role and mechanism in sevoflurane-induced progressive neurotoxicity in rats are rarely reported. Therefore, this study aims to explore the protection of miR-128-3p on sevoflurane-induced neurotoxicity. Hippocampal neurons were isolated and sevoflurane was used to treat the cells. Cell counting kit-8 (CCK-8) was used to detect cell viability. Immunofluorescence was used to detect enrichment of GFAP or βIII tubulin to identify nerve cells. Dual luciferase assay was used to identify the targeted binding relationship between miR-128-3p and NOVA1. The effect of miR-128-3p and sevoflurane on cells regarding apoptosis was detected by flow cytometry. The expression of apoptosis-related protein and oxidative stress-related proteins were detected by western blot. Enzyme-linked immuno-sorbent assay (ELISA) was used to measure inflammatory cytokine levels. Hippocampal neurons' cell viability was significantly decreased by treatment with sevoflurane. MiR-128-3p was down-regulated after sevoflurane treatment in cells. Overexpressed miR-128-3p partially reversed the role of sevoflurane treatment in triggering cell apoptosis, enhancing the expression of Bax and cleaved caspase-3 and inhibiting Bcl-2 expression obviously. Overexpressed miR-128-3p partially reversed the role of sevoflurane treatment in promoting the expression of NOX1and NOX4, and inflammatory cytokine levels by targeting with NOVA1. MiR-128-3p might be a potential therapeutic target for the prevention or treatment of sevoflurane-induced neurotoxicity by targeting with NOVA1.

show abstract

MicroRNAs, a subpopulation of regulators, are involved in breast cancer progression through regulating breast cancer stem cells (Review)

Cited by 14 publications

References 56 publications

Current status and future directions in the treatment of bone metastases from breast cancer

Current status and future directions in the treatment of bone metastases from breast cancer

A modern look at the molecular-biological mechanisms of breast tumours in dogs

The protective effects of miR-128-3p on sevoflurane-induced progressive neurotoxicity in rats by targeting NOVA1

Contact Info

Product

Resources

About